search
Back to results

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

Primary Purpose

Primary IgA Nephropathy

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
RO7434656
Placebo
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary IgA Nephropathy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Primary IgAN, as evidenced by a kidney biopsy performed within 7 years prior to or during screening, without known secondary cause Treatment with maximum tolerated doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for at least 90 days immediately prior to screening Urine Protein-to-Creatinine Ratio (UPCR) ≥ 1 gram per gram (g/g) or urine protein excretion ≥ 1 gram per day (g/day) (with UPCR ≥ 0.8 g/g), all measured from a 24-hour urine collection during screening eGFR ≥ 20 mL/min/1.73 m^2, as calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (Inker et al. 2021a) Female participants of childbearing potential must use adequate contraception Exclusion Criteria: Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 weeks after the final dose of RO7434656 Histopathologic or other evidence of another autoimmune glomerular disease Presence of ≥ 50% crescents on kidney biopsy, sustained doubling of serum creatinine within 3 months prior to screening, or rapidly progressive glomerulonephritis in the opinion of the investigator Glycated Hemoglobin (HbA1c) ≥ 6.5% or a clinical diagnosis of diabetes mellitus of any type Uncontrolled blood pressure, in the investigator's assessment, for 3 months prior to screening or during screening Use of endothelin receptor antagonists, except those approved for use in IgAN Initiation of mineralocorticoid receptor antagonists or endothelin receptor antagonists within 90 days prior to screening or during screening Previous treatment with RO7434656 Use of herbal therapies within 90 days prior to or during screening Treatment with oral or intravenous (IV) corticosteroids with a dose equivalent to ≥ 7.5 milligrams per day (mg/day) of prednisone for 7 days or equivalent to ≥ 5 mg/day of prednisone for 14 days within 90 days prior to screening Treatment with other immunomodulatory agents within 6 months of randomization including, but not limited to, complement inhibitors, alkylating agents (e.g., cyclophosphamide or chlorambucil), or mycophenolate Treatment with a calcineurin inhibitor within 2 months prior to screening or during screening Treatment with anti-CD20 therapy within 9 months of screening or during screening Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study Planned major procedure or major surgery during screening or the study Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Tucson Neuroscience Research - M3 WRRecruiting
  • Southern California Medical Research CenterRecruiting
  • North America Research Institute-San DimasRecruiting
  • Cowry Medical Group LLCRecruiting
  • Sierra Nevada Nephrology ConsultantsRecruiting
  • North Carolina Nephrology, PARecruiting
  • Global Medical Research - M3 WRRecruiting
  • Texas Kidney Institute - DallasRecruiting
  • Pioneer Research SolutionsRecruiting
  • Prolato Clinical Research CenterRecruiting
  • Nephrology Associates of Northern Virginia IncRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

RO7434656

Placebo

Arm Description

Participants will receive subcutaneous (SC) doses of RO7434656 on Days 1, 15, and 29 followed by once every 4 weeks until Week 105. After Week 105, participants may continue blinded treatment or enter open-label treatment up to 1 year after the date at which the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.

Participants will receive SC doses of RO7434656 matching placebo on Days 1, 15, and 29 followed by once every 4 weeks until Week 105. After Week 105, participants may continue blinded treatment or enter open-label treatment up to 1 year after the date at which the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.

Outcomes

Primary Outcome Measures

Change From Baseline in the Urine Protein-to-Creatinine Ratio (UPCR) at Week 37
UPCR will be assessed in urine sampled over 24 hours.

Secondary Outcome Measures

Estimated Glomerular Filtration Rate (eGFR) Slope at Week 105 from Baseline
eGFR will be calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.
Time to the Composite Kidney Failure Endpoint
Time to the composite kidney failure endpoint is defined as receipt of kidney transplantation, need for kidney replacement therapy, or a sustained decline in eGFR of ≥ 30% (requires two consecutive central laboratory eGFR values meeting criteria ≥ 4 weeks apart), whichever occurs first, without the receipt of other immunosuppressive or background therapies for the treatment of IgAN.
Change From Baseline in Fatigue at Week 105
Fatigue will be assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue subscale (FACIT-F). The FACIT-F Scale is a 13-item scale used to measure self-reported fatigue. Items are assessed on a 5-point Likert scale, with responses ranging from 0 for "not at all" to 4 for "very much". The total raw score is the sum of the values of each scored question and ranges from 0 to 52. A higher score indicates less fatigue.
Change From Baseline in Symptoms and Health-Related Quality of Life at Week 105 as Assessed Using the Kidney Disease and Quality of Life 36-Item (KDQOL-36) Short Form
The KDQOL-36 is an abbreviated questionnaire that combines generic and disease-specific components to assess participant's health-related quality of life. This 36-item questionnaire includes the Short Form 12 (SF-12), Version 1 (12 items) and 3 disease-related domains, symptoms/problems (12 items), burden of kidney disease (4 items), and effects of kidney disease (8 items). It uses a recall of 4 weeks, and items are assessed on 3- to 5-point Likert scales or with a dichotomous response option. Higher score indicates better health. The raw scores are transformed linearly to a range of 0 to 100, with higher scores indicating better health.
Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)
Plasma Concentration of RO7434656

Full Information

First Posted
March 22, 2023
Last Updated
October 4, 2023
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT05797610
Brief Title
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Acronym
IMAGINATION
Official Title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 8, 2023 (Actual)
Primary Completion Date
September 30, 2026 (Anticipated)
Study Completion Date
September 30, 2030 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary IgA Nephropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
428 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RO7434656
Arm Type
Experimental
Arm Description
Participants will receive subcutaneous (SC) doses of RO7434656 on Days 1, 15, and 29 followed by once every 4 weeks until Week 105. After Week 105, participants may continue blinded treatment or enter open-label treatment up to 1 year after the date at which the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive SC doses of RO7434656 matching placebo on Days 1, 15, and 29 followed by once every 4 weeks until Week 105. After Week 105, participants may continue blinded treatment or enter open-label treatment up to 1 year after the date at which the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.
Intervention Type
Drug
Intervention Name(s)
RO7434656
Intervention Description
RO7434656 will be administered subcutaneously per schedule as specified.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching placebo will be administered subcutaneously per schedule as specified.
Primary Outcome Measure Information:
Title
Change From Baseline in the Urine Protein-to-Creatinine Ratio (UPCR) at Week 37
Description
UPCR will be assessed in urine sampled over 24 hours.
Time Frame
Baseline, Week 37
Secondary Outcome Measure Information:
Title
Estimated Glomerular Filtration Rate (eGFR) Slope at Week 105 from Baseline
Description
eGFR will be calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.
Time Frame
Baseline, Week 105
Title
Time to the Composite Kidney Failure Endpoint
Description
Time to the composite kidney failure endpoint is defined as receipt of kidney transplantation, need for kidney replacement therapy, or a sustained decline in eGFR of ≥ 30% (requires two consecutive central laboratory eGFR values meeting criteria ≥ 4 weeks apart), whichever occurs first, without the receipt of other immunosuppressive or background therapies for the treatment of IgAN.
Time Frame
Up to approximately 7 years
Title
Change From Baseline in Fatigue at Week 105
Description
Fatigue will be assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue subscale (FACIT-F). The FACIT-F Scale is a 13-item scale used to measure self-reported fatigue. Items are assessed on a 5-point Likert scale, with responses ranging from 0 for "not at all" to 4 for "very much". The total raw score is the sum of the values of each scored question and ranges from 0 to 52. A higher score indicates less fatigue.
Time Frame
Baseline, Week 105
Title
Change From Baseline in Symptoms and Health-Related Quality of Life at Week 105 as Assessed Using the Kidney Disease and Quality of Life 36-Item (KDQOL-36) Short Form
Description
The KDQOL-36 is an abbreviated questionnaire that combines generic and disease-specific components to assess participant's health-related quality of life. This 36-item questionnaire includes the Short Form 12 (SF-12), Version 1 (12 items) and 3 disease-related domains, symptoms/problems (12 items), burden of kidney disease (4 items), and effects of kidney disease (8 items). It uses a recall of 4 weeks, and items are assessed on 3- to 5-point Likert scales or with a dichotomous response option. Higher score indicates better health. The raw scores are transformed linearly to a range of 0 to 100, with higher scores indicating better health.
Time Frame
Baseline, Week 105
Title
Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)
Time Frame
Up to approximately 7 years
Title
Plasma Concentration of RO7434656
Time Frame
Up to approximately 7 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Primary IgAN, as evidenced by a kidney biopsy performed within 7 years prior to or during screening, without known secondary cause Treatment with maximum tolerated doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for at least 90 days immediately prior to screening Urine Protein-to-Creatinine Ratio (UPCR) ≥ 1 gram per gram (g/g) or urine protein excretion ≥ 1 gram per day (g/day) (with UPCR ≥ 0.8 g/g), all measured from a 24-hour urine collection during screening eGFR ≥ 20 mL/min/1.73 m^2, as calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (Inker et al. 2021a) Female participants of childbearing potential must use adequate contraception Exclusion Criteria: Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 weeks after the final dose of RO7434656 Histopathologic or other evidence of another autoimmune glomerular disease Presence of ≥ 50% crescents on kidney biopsy, sustained doubling of serum creatinine within 3 months prior to screening, or rapidly progressive glomerulonephritis in the opinion of the investigator Glycated Hemoglobin (HbA1c) ≥ 6.5% or a clinical diagnosis of diabetes mellitus of any type Uncontrolled blood pressure, in the investigator's assessment, for 3 months prior to screening or during screening Use of endothelin receptor antagonists, except those approved for use in IgAN Initiation of mineralocorticoid receptor antagonists or endothelin receptor antagonists within 90 days prior to screening or during screening Previous treatment with RO7434656 Use of herbal therapies within 90 days prior to or during screening Treatment with oral or intravenous (IV) corticosteroids with a dose equivalent to ≥ 7.5 milligrams per day (mg/day) of prednisone for 7 days or equivalent to ≥ 5 mg/day of prednisone for 14 days within 90 days prior to screening Treatment with other immunomodulatory agents within 6 months of randomization including, but not limited to, complement inhibitors, alkylating agents (e.g., cyclophosphamide or chlorambucil), or mycophenolate Treatment with a calcineurin inhibitor within 2 months prior to screening or during screening Treatment with anti-CD20 therapy within 9 months of screening or during screening Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study Planned major procedure or major surgery during screening or the study Other protocol-defined inclusion/exclusion criteria may apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
WA43966 https://forpatients.roche.com/
Phone
888-662-6728 (U.S. Only)
Email
global-roche-genentech-trials@gene.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
Tucson Neuroscience Research - M3 WR
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85710
Country
United States
Individual Site Status
Recruiting
Facility Name
Southern California Medical Research Center
City
La Palma
State/Province
California
ZIP/Postal Code
90623
Country
United States
Individual Site Status
Recruiting
Facility Name
North America Research Institute-San Dimas
City
San Dimas
State/Province
California
ZIP/Postal Code
91773
Country
United States
Individual Site Status
Recruiting
Facility Name
Cowry Medical Group LLC
City
Acworth
State/Province
Georgia
ZIP/Postal Code
30101
Country
United States
Individual Site Status
Recruiting
Facility Name
Sierra Nevada Nephrology Consultants
City
Reno
State/Province
Nevada
ZIP/Postal Code
89511
Country
United States
Individual Site Status
Recruiting
Facility Name
North Carolina Nephrology, PA
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27609
Country
United States
Individual Site Status
Recruiting
Facility Name
Global Medical Research - M3 WR
City
Dallas
State/Province
Texas
ZIP/Postal Code
75224
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Kidney Institute - Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Individual Site Status
Recruiting
Facility Name
Pioneer Research Solutions
City
Houston
State/Province
Texas
ZIP/Postal Code
077099
Country
United States
Individual Site Status
Recruiting
Facility Name
Prolato Clinical Research Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77054
Country
United States
Individual Site Status
Recruiting
Facility Name
Nephrology Associates of Northern Virginia Inc
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22033
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Learn more about this trial

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

We'll reach out to this number within 24 hrs